

Accepted Manuscript

The blood proteomic signature of early-onset pediatric atopic dermatitis shows systemic inflammation and is distinct from adult, longstanding disease

Patrick M. Brunner, MD, MSc, Helen He, BS, Ana B. Pavel, PhD, Tali Czarnowicki, MD, MSc, Rachel Lefferdink, MD, Taylor Erickson, BS, Talia Canter, BS, Neha Puar, DO, Stephanie Rangel, PhD, Kunal Malik, MD, Yeriel Estrada, BS, James G. Krueger, MD, PhD, Emma Guttman-Yassky, MD, PhD, Amy S. Paller, MS, MD



PII: S0190-9622(19)30628-0

DOI: <https://doi.org/10.1016/j.jaad.2019.04.036>

Reference: YMJD 13382

To appear in: *Journal of the American Academy of Dermatology*

Received Date: 30 January 2019

Revised Date: 12 April 2019

Accepted Date: 13 April 2019

Please cite this article as: Brunner PM, He H, Pavel AB, Czarnowicki T, Lefferdink R, Erickson T, Canter T, Puar N, Rangel S, Malik K, Estrada Y, Krueger JG, Guttman-Yassky E, Paller AS, The blood proteomic signature of early-onset pediatric atopic dermatitis shows systemic inflammation and is distinct from adult, longstanding disease, *Journal of the American Academy of Dermatology* (2019), doi: <https://doi.org/10.1016/j.jaad.2019.04.036>.

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

1 **Capsule summary**

- 2 • Early-onset pediatric patients with moderate-to-severe atopic dermatitis already show
- 3 systemic signs of inflammation within months of onset and before chronic disease develops.
- 4 • These data suggest the need for early intervention in pediatric atopic dermatitis to prevent
- 5 disease chronicity and perhaps development of atopic comorbidities (“atopic march”) and
- 6 other associated disorders.

Article type: Original article

Title: The blood proteomic signature of early-onset pediatric atopic dermatitis shows systemic inflammation and is distinct from adult, longstanding disease

Patrick M. Brunner, MD, MSc,¹ Helen He, BS,² Ana B. Pavel, PhD,² Tali Czarnowicki, MD, MSc,^{1,2} Rachel Lefferdink, MD,³ Taylor Erickson, BS,³ Talia Canter, BS,³ Neha Puar, DO,³ Stephanie Rangel, PhD,³ Kunal Malik, MD,² Yeriel Estrada, BS,² James G. Krueger, MD, PhD,¹ Emma Guttman-Yassky, MD, PhD^{1,2*} and Amy S. Paller, MS, MD,^{3*}

¹ The Laboratory for Investigative Dermatology, The Rockefeller University, 1230 York Avenue, New York, NY 10065, USA

² Department of Dermatology and the Laboratory for Inflammatory Skin Diseases, Icahn School of Medicine at Mount Sinai, 1 Gustave L. Levy Place, New York, NY 10029, USA

³ Department of Dermatology, Northwestern University Feinberg School of Medicine, 676 North St. Clair Street, Chicago, IL 60611, USA

*Equal contribution

Corresponding author:

Amy S. Paller, MS, MD
Department of Dermatology
Northwestern University Feinberg School of Medicine
676 N Saint Clair
Chicago IL 60611
Email: apaller@northwestern.edu
Telephone: 312-695-3721; Fax: 312-695-0664

27

28 **Funding sources:** This work was funded by a research grant from Galderma S.A. PMB was
29 supported in part by grant # UL1 TR00043 from the National Center for Advancing Translational
30 Sciences (NCATS), National Institutes of Health (NIH) Clinical and Translational Science Award
31 (CTSA) program. NP was supported by a Dermatology Fellowship Grant from Pfizer. The study
32 was also supported by the Northwestern Skin Disease Research Center (NIAMS P30
33 AR057216) and the Northwestern University Clinical And Translational Sciences (NUCATS)
34 Institute (UL1TR001422).

35

36 **Conflicts of Interest:** PMB has received personal fees from LEO Pharma, Pfizer, Sanofi
37 Genzyme, Celgene and Lilly. NP received fellowship support from Pfizer. JGK is an employee of
38 the Rockefeller University and has received research support (grants paid to his institution)
39 and/or personal fees from Pfizer, Amgen, Janssen, Lilly, Merck, Novartis, Kadmon, Dermira,
40 Boehringer, Innovaderm, Kyowa, BMS, Serono, BiogenIdec, Delenex, AbbVie, Sanofi, Baxter,
41 Paraxel, Xenoport, and Kineta. EGY is an employee of Mount Sinai and has received research
42 funds (grants paid to her institution) from: Abbvie, Celgene, Eli Lilly, Janssen, Medimmune/Astra
43 Zeneca, Novartis, Pfizer, Regeneron, Vitae, Glenmark, Galderma, Asana, Innovaderm, Dermira,
44 and UCB. EGY is also a consultant for Sanofi Aventis, Regeneron, Stiefel/GlaxoSmithKline,
45 MedImmune, Celgene, Anacor, AnaptysBio, Dermira, Galderma, Glenmark, Novartis, Pfizer,
46 Vitae, Leo Pharma, Abbvie, Eli Lilly, Kyowa, Mitsubishi Tanabe, Asana Biosciences, and
47 Promius. ASP is an investigator for Galderma, Incyte, Leo, Pfizer, and Regeneron (grants paid
48 to Northwestern Univ.) and has received honoraria related to AD consulting from AbbVie,
49 Asana, Boehringer, Dermavant, Dermira, Eli Lilly, Forte, Galderma, Leo, Matrisys, Menlo
50 Therapeutics, Morphosys/Galapagos, Novartis, Pfizer, Regeneron, and Sanofi-Genzyme. The
51 rest of the authors declare that they have no relevant conflicts of interest.

52

IRB approval status: Reviewed and approved by local IRBs.

Reprint requests: none

Manuscript word count: 2,488 words

Abstract word count: 199

Capsule summary word count: 50

References: 72

Figures: 3

Supplementary figures: 0

Tables: 2

Supplementary tables: 0

Attachments: 0

Keywords: Atopic dermatitis; infant; pediatric; peripheral blood; multiplex assay; proximity
extension assay; OLINK;

Abstract

Background: Despite increasing evidence that adults with longstanding atopic dermatitis (AD) have systemic inflammation, little is known about systemic inflammation in recent-onset early pediatric AD.

Objective: To analyze blood inflammatory proteins of early pediatric AD.

Methods: Using high-throughput proteomics (proximity extension assay), we assessed 257 inflammatory and cardiovascular risk proteins in blood of 30 children with moderate-to-severe AD <5 years of age (within 6 months of onset), compared to age-matched pediatric controls and adult AD.

Results: In pediatric AD blood, Th2 (CCL13, CCL22) and Th17 (PI3/elafin) markers were increased, together with markers of tissue remodelling (MMP3/9/10, uPAR), endothelial activation (E-Selectin), T-cell activation (IL2RA), neutrophil activation (myeloperoxidase), lipid metabolism (FABP4), and growth factors (FGF21, TGF- α). Total numbers of dysregulated proteins were smaller (n=22) than in adult AD (n=61). Clinical severity scores were positively correlated with receptors for IL-33 and IL-36, and inversely correlated with some Th1 markers (IFN- γ , CXCL11).

Limitations: Different baseline expression levels in healthy pediatric vs. adult samples.

Conclusions: Within months of pediatric AD onset, systemic immune activation is present, with Th2/Th17 skewing but otherwise different proteomic patterns from adult AD. Future correlation of proteomic patterns with disease course, comorbidity development, and drug response may yield predictive biomarkers.

Abbreviations:

94	AD: Atopic dermatitis
95	BSA: Body surface area
96	DECR1: 2,4-dienoyl-CoA reductase
97	EASI: Eczema Area and Severity Index
98	EGF: Epidermal growth factor
99	FABP4: Fatty acid binding protein-4
100	FCH: Fold change
101	FDR: False discovery rate
102	FGF: Fibroblast growth factor
103	HSP: Heat shock protein
104	IFN: Interferon
105	KLK: Kallikrein
106	LTBR: Lymphotoxin beta receptor
107	MADAD: Meta-analysis derived atopic dermatitis
108	M-CSF: Macrophage colony-stimulating factor
109	MB: Myeloblastin
110	MMP: Matrix metalloproteinase
111	MPO: Myeloperoxidase
112	PAR-1: Protease-activated receptor
113	PBMC: Peripheral blood mononuclear cell
114	PI3: Peptidase inhibitor-3
115	SCORAD: SCORing Atopic Dermatitis
116	SELE: E-Selectin
117	TARC: Thymus and activation regulated chemokine
118	TEWL: Transepidermal water loss
119	

120 TGF: Transforming growth factor

121 uPAR: Urokinase receptor

122

ACCEPTED MANUSCRIPT

Introduction

Atopic dermatitis (AD) is often associated with allergic comorbidities such as asthma, rhinoconjunctivitis, and food allergies.¹ Increasing evidence in adults suggests that AD is also associated with cardiovascular disease,²⁻⁶ potentially rooted in decades of chronic systemic inflammation, as the majority of AD cases begin before 5 years of age. Consistently, adults with moderate-to-severe AD show increases in multiple circulating inflammatory mediators,^{7,8} including cardiovascular risk proteins, and increased frequencies of activated blood T-cells.⁹ While most data on systemic inflammation are based on studies in adults with decades of chronic disease, blood-profiling from early pediatric AD (within the first months of disease onset) is limited. Increased odds of obesity, hypertension, and hyperlipidemia have been noted in children aged 0-17 years.¹⁰ Pediatric AD is also associated with increases in autism spectrum and attention deficit hyperactivity disorders (ADHD), particularly among those with earlier-onset or more severe AD.¹¹ The link of ADHD with pediatric AD is hypothesized to relate to early exposure of the brain to inflammatory cytokines.¹² Finding biomarkers for comorbidity risk in blood, given the challenge of obtaining skin biopsies, would be ideal.

Recent profiling studies in infants, young children^{13,14} and adolescents¹⁵ show that early AD is Th2, but also Th17 polarized in skin.^{13,14} Blood studies have investigated smaller numbers of pre-selected markers,¹⁵⁻⁴⁰ and have identified biomarkers correlating with disease activity, especially Th2-associated mediators (i.e., IL-31, CCL17 (TARC), CCL22, and CCL27).³²⁻³⁶ Increases in memory T-cells have been observed throughout life,⁴¹⁻⁴⁴ and we recently described expansion of Th2 T-cells, but not other polar T-cell subsets, in early pediatric AD blood.²⁹ Overall, newborns show lower percentages of CD4⁺ and CD8⁺ IFN- γ -producing PBMCs,⁴³ and further reduction in IFN- γ secretion predisposes to atopy.¹⁸ Consistently, increases in Th2 activation and lower frequencies of IFN- γ responses early in life are suggested to increase the risk of developing AD.^{16,17} However, unlike in adults with chronic AD,^{7,8,45} a broad, array-based proteomic approach to characterize the peripheral blood phenotype of early AD is lacking.

Methods

Patients

Thirty children (≤ 5 years) with moderate-to-severe AD within 6 months of disease onset were included (Table 1). Exclusion criteria were active skin infection, use of topical glucocorticosteroids/ immunomodulators within 1 week, and systemic immunosuppressants within 4 weeks. Before study inclusion, parents signed IRB-approved written consent, according to the declaration of Helsinki. Clinical severity scores included SCORAD (SCORing of Atopic Dermatitis), EASI (Eczema Area and Severity Index), BSA (Body surface area in %) and the ADQ pruritus score. Transepidermal water loss (TEWL) of lesional and non-lesional skin was performed by using a Tewameter® (Cologne, Germany). Symptoms of current food allergy, allergic rhino-conjunctivitis, and asthma were present in 4, 2, and no children, respectively. Nineteen age-matched control samples were obtained from healthy children without personal or family history of atopy. Proteomic results were compared to blood data from 58 adult AD patients with comparable severity, as well as adult controls, both from a published cohort (Table 1).⁴⁶ Transcriptomic skin biopsy data (Affymetrix Human U133Plus 2.0 arrays, Affymetrix, Santa Clara, Calif.) from a published cohort of 19 lesional pediatric AD (≤ 5 years of age and within 6 months of disease onset) and 17 pediatric healthy control skin samples was used for blood-skin comparisons.⁴⁷ Transcriptomic whole blood data (Affymetrix Human U133Plus 2.0 arrays) from 15 of our pediatric AD patients (same blood draw) was available for blood cell-plasma correlations from a previously published dataset.⁴⁸

Blood protein quantification

Blood was collected, centrifuged, and plasma samples were stored at -80°C until further processing. Aliquots were analyzed by a proteomic OLINK Proseek® multiplex assay (a proximity extension assay with oligonucleotide-labeled antibody probe pairs).⁴⁹⁻⁵¹ This method

quantifies hundreds of protein levels from 10µL serum using an antibody-mediated detection system linked to synthetic DNA for quantification by a real-time PCR platform.⁵⁰ Samples were analyzed using OLINK Inflammation I, cardiovascular disease (CVD) II and CVD III panels, containing 257 established and exploratory markers.⁵⁰

Statistical analyses

Analyses were performed using R-language (R-project.org) and packages available through the Bioconductor Project (www.bioconductor.org).⁴⁶ Quality control of OLINK data was performed using their standard quality control pipeline (QC).^{49,50} Protein expression profiles were modeled using linear models for high-throughput data on R's *limma* framework. The model used disease as a factor and age, gender, and BMI as covariates. FCHs for comparisons were estimated using an empirical Bayesian method⁵² and hypothesis testing was conducted using contrasts under the general framework for linear models in the *limma* package. P-values from the moderated (paired) t-test were adjusted for multiple hypotheses using the Benjamini–Hochberg procedure. Genes with fold change (FCH)>1.3 and false discovery rate (FDR)<0.1 were considered differentially expressed. Protein annotations and gene-protein relationships were obtained by using the UniProt ID and R's *AnnotationDbi* package.

Results

Proteomic differences in peripheral blood between early pediatric and adult AD

Differentially expressed proteins were plotted in a heat map (Figure 1). Consistent with the Th2- and Th17-skewed inflammatory milieu described in pediatric skin,⁵³ Th2 (CCL13, CCL22) and Th17 (PI3/elafin) markers were most strongly increased in pediatric blood compared to healthy control. We also found increases in E-Selectin (SELE), a cell adhesion molecule of endothelial cells. Other inflammatory markers upregulated in pediatric AD included proteins involved in tissue remodelling (MMP3, MMP9, MMP10, myeloblastin MB), T-cell activation (IL2RA or CD25, a receptor component of the T-cell growth factor IL-2), lipid metabolism (fatty acid binding protein-4 (FABP4), a treatment target in cardiovascular disease and diabetes⁵⁴), and angiogenesis/ coagulation (uPAR). We also found increases in growth factors FGF21 (fibroblast growth factor-21), a liver-derived molecule that is increased in insulin-resistant morbidities such as type-2 diabetes mellitus or obesity,⁵⁵ and TGF- α , an analogue of epidermal growth factor (EGF) mediating epithelial development, epidermal hyperproliferation, and tumorigenesis. Other upregulated molecules included the potent leukocyte chemoattractants CCL2 and CCL15, neutrophil protein myeloperoxidase (MPO), lymphotoxin beta receptor LTBR (a member of the tumor necrosis factor receptor superfamily involved in lymphoid tissue development), and the IL-1 decoy receptor IL1R2, which limits IL-1- α/β pathway activation by preventing receptor binding of IL-1 α and IL-1 β .

Overall, early-onset pediatric AD had a smaller set of upregulated proteins (n=22) than adults with longstanding AD (n=61) (Figure 1). Only 3 proteins (CCL13, MMP10, TGF- α) were upregulated vs. controls in both pediatric and adult blood. Upregulated proteins in adult AD included a broader array of Th2 (CCL17, CCL13, IL-13) and Th17 (CCL20) associated markers, but also of Th1 (CXCL9, CXCL10, CXCL11, IFN- γ) markers, which were not upregulated in pediatric AD blood, consistent with Th1 activation as a marker of AD chronicity.⁵⁶

Among healthy controls, levels of Th1 (CXCL9, CXCL10, CXCL11), Th2 (CCL13, CCL17), Th1/Th17 (IL12B – IL12/IL23p40) and Th17 (CCL20) associated proteins, the regulatory cytokine IL-10, and markers of general inflammation (MMP12), endothelial activation (E-Selectin/SELE), the neutrophil chemoattractant CXCL6, and the beta-oxidation enzyme 2,4-dienoyl-CoA reductase (DECR1) were all greater in young children vs. adult HCs (Figure 1). In contrast, adult HCs had increased levels of chemokines CCL28 and CCL8 (which have antimicrobial activity),^{57,58} the hematopoietic growth factor IL-7, and matrix metalloproteinases 3 and 9 compared to pediatric HCs (Figure 1).

We also performed Spearman correlation of absolute blood (plasma) protein levels with matching whole blood cell mRNA expression in the 15 AD children for whom the same sample was available for both assays. Although a few markers were significantly correlated ($p < 0.05$; Table 2), none of these were among the 22 markers upregulated in pediatric AD plasma, suggesting the independent regulation of soluble blood protein and blood cell gene expression patterns in early-onset pediatric AD.

Skin and blood comparisons

We next compared upregulated blood proteins (FCH > 1.3 vs. HC) with corresponding upregulated skin mRNA levels from a recently described similar pediatric AD population.⁴⁷ Within our panels, there were only 9 shared upregulated inflammatory and cardiovascular markers: PI3/elafin (Th17), CCL22 (Th2), and markers of endothelial activation (E-Selectin/SELE) and tissue remodelling (MMP10), T-cell activation (IL2RA), the growth factor TGF- α , the chemokine CCL2, the lymphotoxin beta receptor LTBR, and kallikrein-6/KLK6 (Figure 2).

Correlations between proteomic markers and skin disease scores

Given the limited number of circulating markers increased in both blood and skin, we focused on blood protein biomarkers of AD severity, regardless of skin expression. We plotted blood proteomic levels and clinical severity measures (SCORAD, EASI, BSA) in a correlation heat map (Figure 3). We also added lesional and non-lesional transepidermal water loss (TEWL), a functional measure of the skin barrier,⁵⁹ and body mass index (BMI), which is correlated with cardiovascular risk.⁶⁰ Positive correlations with SCORAD, EASI and BSA (Figure 3, blue box) were found for the soluble cytokine receptors ST2 (IL1RL1) and IL1RL2. ST2 is the receptor for the Th2-inducing cytokine IL-33,⁶¹ which is critically involved in IL-33-mediated food allergy via skin sensitization.⁶² IL1RL2 is a receptor component for IL-36 (IL-36A, IL-36B, IL-36G), which is increased in skin lesions of early-onset pediatric, but not adult AD.¹³ BSA and SCORAD were also positively correlated with the endothelial activation marker E-Selectin (SELE). BSA was positively correlated with MMP-12, kallikrein-6 (KLK6) and CCL22. Other positive correlations between SCORAD, EASI and/or BSA were found for heat shock protein HSP27, protease-activated receptor PAR-1, the IL-1 decoy receptor IL-1RT2, and galectin-3 (Gal-3) (Figure 3, blue box). Surprisingly, the level of CCL17 (TARC), considered the most reliable serum biomarker of AD skin disease activity in adults and children,²⁸ was not correlated with disease severity.

Negative correlations between skin activity scores (SCORAD, BSA and/or EASI) and blood proteins (green box) were found with the Th1-associated markers IFN- γ , CXCL11, and CCL2 (MCP-1). Skin scores were also negatively associated with neutrophil chemo-attractants CXCL5 and CXCL6, the hematopoietic growth factor M-CSF (CSF-1), leukemia inhibitory factor receptor (LIF-R), matrix metalloproteinase-1 (MMP1), the beta-oxidation enzyme DECR1, and fractalkine (CX3CL1). Some were also negatively correlated with pruritus or lesional TEWL (black box). BMI only showed weak correlations with PI3/elafin, IL-16 and IL-2RA (Figure 3). We also found a larger correlation cluster (pink box) comprising the general inflammation marker MMP12 with PI3/elafin (Th17), E-Selectin (endothelial activation), CCL22 (Th2), and others, indicating their

270 common regulation.

Discussion

Whole skin profiling studies of infants and young children with recent-onset AD have revealed considerable differences from adults with longstanding disease.^{13,14} This study extends these differences to blood using a large-scale proteomic platform. Overall, blood profiles of early pediatric AD show Th2/Th17 skewing of soluble proteomic markers, with absence of the Th1 upregulation seen in adults with AD, consistent with the skin immune phenotype in early AD,^{13,14} and complementing our recent paper⁴⁸ showing increased eosinophil and Th2 mRNA markers in early pediatric AD whole blood cells on a transcriptomic level, with decreases in IFN- γ /Th1 that were also negatively correlated with clinical severity. Together with increases in inflammatory markers of endothelial cell activation (E-Selectin) and tissue remodeling (MMP3, MMP9, MMP10, uPAR), our data emphasize the systemic alterations within months of disease onset, potentially suggesting the need for more aggressive intervention before the establishment and perpetuation of chronic disease.

Blood fractalkine (CX3CL1), which is involved in T-cell retention in inflamed tissue and leukocyte adhesion to endothelial cells,⁶³ is significantly increased in adult AD^{7,64} and was previously reported to be increased in pediatric AD, correlating with clinical severity.⁶⁵ In our study, CX3CL1 negatively correlated with SCORAD, which may reflect the early disease, young age, and lack of disease chronicity of our AD patients; the age of previously published children was 5.4 ± 2.2 years (mean $\pm$ SD)⁶⁵ vs. our cohort of 1.8 ± 1.6 years.

Surprisingly, the previously described positive correlation of SCORAD with CCL17 (TARC) was absent.^{34,66} It is unlikely that the difference reflects our evaluation of plasma vs. the more typical serum samples. However, most studies showing correlations of CCL17 with AD severity in children involved patients older than 4 years of age.²⁸ The few studies that evaluated blood in infants and/or toddlers investigated Asian populations,^{28,34,36} while our patients were mostly

Caucasians/European Americans. The only other exception is a study by Ahrens et al. in Germany, which showed a correlation between CCL17 levels and SCORAD in infants who were food and airborne-sensitized, but not those who showed no food sensitization.⁶⁷ Our infants with AD largely had no allergic comorbidities (food allergies, asthma, or allergic rhinoconjunctivitis), although specific IgEs to detect food sensitization were not tested. Thus, the difference may, in part, relate to the age, recent AD onset, and limited atopic profile of our cohort.

We also compared blood protein profiles with both blood and skin transcriptomic profiles of early AD. We did not find correlations between soluble blood protein levels that were upregulated in pediatric AD and mRNA expression of corresponding whole blood cell samples, suggesting that blood proteins might be derived from sources independent of circulating blood cells, such as the skin. When comparing blood proteins with skin mRNA levels, we found a limited set of mutually upregulated markers, including those associated with Th2 and Th17 responses. Differences between extracellular vs. intracellular expression and post-transcriptional changes could also account for inconsistencies between protein and mRNA levels.

Food sensitization tends to appear in pediatric patients with more severe AD.^{67,68} In this regard, we found strong positive correlations between soluble blood ST2 levels and pediatric AD skin severity scores. ST2 (IL1RL1), the IL-33 receptor, is highly expressed on Th2 cells, mast cells and ILC2 cells,⁶⁹ mediating IL-33-mediated food and dust mite allergy via skin sensitization in mouse models.^{62,70} Its role in humans, however, is less clear. Despite the fact that our pediatric patients did not (yet) suffer from allergic comorbidities, the observed correlation of ST2 expression with early disease severity (which has not been observed in older children and adults with AD⁷¹) suggests the need for investigation of the IL-33/ST2 axis in longitudinal studies beginning early after AD onset. Nevertheless, these data might suggest that IL-33-targeting

strategies, which are being tested in adults (NCT02920021, NCT03533751), could benefit some children with early AD.⁷²

Blood IL1RL2, the receptor for IL-36 cytokines, was also positively correlated with skin disease. IL-36 cytokines are up-regulated in infant AD but, much less so, in adult AD skin,¹³ and might thus be a biomarker specific for early disease. Furthermore, anti-IL-36 treatment approaches, which are being tested for pustular psoriasis (NCT03135548, NCT02978690), may also be applicable for children with AD.

Low IFN- γ responses have been described as a risk factor for developing AD.¹⁶⁻¹⁸ The negative correlation of skin severity with Th1 markers (IFN- γ , CXCL11, and CCL2) was also present in our blood samples, together with negative correlations of multiple additional markers, including mediators of neutrophil chemotaxis (CXCL5, CXCL6). One might speculate that these molecules could have a protective role, but future studies will be needed to confirm this hypothesis.

Overall, our study sheds a more comprehensive light on proteomic regulation in the peripheral blood of early AD. This initial stage might be an attractive window for novel therapeutic approaches to treat both the skin disease and early systemic inflammation. Although blood proteomic, as well as previously published mRNA investigations⁴⁸, elicited only a limited number of regulated markers, proteomic blood profiling (potentially in conjunction with non-invasive skin investigations such as tape stripping) during trials or longitudinally might identify predictive markers of disease response and natural course of the AD in children, including the development of multimorbidities.

Table 1. Baseline characteristics of study cohorts for proteomic blood analyses.

	AD Pediatric	Healthy Pediatric	p-value pediatric	AD Adult	Healthy Adult	p-value adult
Sample size	n= 30	n= 19		n= 58	n= 18	
Age (mean, SD)	1.8 (1.6)	2.1 (1.3)	0.526	40.3 (15.2)	41.3 (10.3)	0.801
BMI (mean, SD)	17.1 (1.9)	15.9 (1.7)	0.891	27.8 (6.1)	27.6 (4.4)	0.891
SCORAD (mean, SD)	52.4 (16.7)	NA		54.3 (13.1)	NA	
Gender			0.733			0.474
F (n, %)	13 (43.3%)	10 (52.6%)		27 (46.6%)	6 (33.3%)	
M (n, %)	17 (56.7%)	9 (47.4%)		31 (53.4%)	12 (66.7%)	
Race			0.087			0.656
Asian (n, %)	6 (20.0%)	0 (0.0%)		15 (25.9%)	3 (16.7%)	
Black (n, %)	6 (20.0%)	3 (15.8%)		23 (39.7%)	9 (50.0%)	
White (n, %)	18 (60.0%)	16 (84.2%)		20 (34.5%)	6 (33.3%)	

Table 2. Correlation of plasma protein levels (OLINK) with corresponding whole blood mRNA levels (Affymetrix) in pediatric blood samples. Protein and mRNA data from the same individual were available for 15 pediatric AD patients. Spearman correlation was limited to markers that were detectable in both OLINK and Affymetrix (mRNA) assays (n=202 markers, data not shown); Correlations with a $p \leq 0.05$ are depicted in this table.

Marker	Correlation coefficient (r)	P-value
TFRC	0.689285714	0.0058
CD274	0.620790837	0.014
CXCL1	-0.6	0.02
HSPG2	-0.591607978	0.02
IL1R1	0.592857143	0.022
THBD	-0.589285714	0.023
PAPPA	0.565267106	0.028
TNFSF11	0.553571429	0.035
TNFRSF10A	0.542857143	0.039
CA5A	-0.536774032	0.039
TNFSF13B	0.528571429	0.045
CD93	-0.521428571	0.049

Figure legends

Figure 1. Atopic Dermatitis. Heat map of differentially expressed genes (FCH>1.3, FDR<0.1), with markers grouped by unsupervised hierarchical clustering (data-driven organization of patterns into useful groups) in either adult or pediatric AD compared to their age-matched controls. +p<0.1, *p<0.05, **p<0.01, ***p<0.001 are the p-values for significance vs. comparator, as shown above each column. Note that the expression of many blood proteins is higher or lower in pediatric vs. adult AD, but not when compared with age-matched pediatric healthy control blood. Red color denotes higher and blue color denotes lower mean expression levels.

Figure 2. Atopic Dermatitis. Scatter plots comparing upregulated differentially expressed genes in skin (mRNA levels) and proteins in blood (OLINK) (FCH>1.3, FDR<0.1), depicted as fold-change (FCH) over respective healthy controls; the size of the circle represents the absolute difference between log2-FCH blood and skin. Markers significantly upregulated in both blood and skin are indicated in red letters.

Figure 3. Atopic Dermatitis. Heat map of Spearman correlations between blood proteins and clinical scores such as SCORAD (SCORing Atopic Dermatitis, which captures itch and insomnia), EASI (Eczema Area and Severity Index), BSA (Body surface area), pruritus intensity, BMI (body mass index) and TEWL (transepidermal water loss); markers were selected for top significance levels for positive or negative correlations with SCORAD; *p<0.05, **p<0.01, ***p<0.001. Red denotes positive and blue denotes negative correlations. Colored boxes denote correlation clusters with inflammatory markers (pink box) and clinical disease characteristics (blue for positive and green for negative correlations with SCORAD, BSA, and EASI severity scores, black for negative correlations with pruritus and TEWL). Clinical scores are in bold font.

References

1. Weidinger S, Novak N. Atopic dermatitis. *Lancet* 2016;387:1109-22.
2. Brunner PM, Silverberg JI, Guttman-Yassky E, et al. Increasing Comorbidities Suggest that Atopic Dermatitis Is a Systemic Disorder. *J Invest Dermatol* 2017;137:18-25.
3. Silverberg JI. Association between adult atopic dermatitis, cardiovascular disease, and increased heart attacks in three population-based studies. *Allergy* 2015;70:1300-8.
4. Silverberg JI, Greenland P. Eczema and cardiovascular risk factors in 2 US adult population studies. *J Allergy Clin Immunol* 2015;135:721-8 e6.
5. Silverwood RJ, Forbes HJ, Abuabara K, et al. Severe and predominantly active atopic eczema in adulthood and long term risk of cardiovascular disease: population based cohort study. *BMJ* 2018;361:k1786.
6. Silverberg JI, Gelfand JM, Margolis DJ, et al. Association of atopic dermatitis with allergic, autoimmune, and cardiovascular comorbidities in US adults. *Ann Allergy Asthma Immunol* 2018;121:604-12 e3.
7. Brunner PM, Suarez-Farinas M, He H, et al. The atopic dermatitis blood signature is characterized by increases in inflammatory and cardiovascular risk proteins. *Sci Rep* 2017;7:8707.
8. Thijs JL, Strickland I, Bruijnzeel-Koomen C, et al. Serum biomarker profiles suggest that atopic dermatitis is a systemic disease. *J Allergy Clin Immunol* 2018;141:1523-6.
9. Czarnowicki T, Malajian D, Shemer A, et al. Skin-homing and systemic T-cell subsets show higher activation in atopic dermatitis versus psoriasis. *J Allergy Clin Immunol* 2015;136:208-11.
10. Silverberg JI. Atopic disease and cardiovascular risk factors in US children. *J Allergy Clin Immunol* 2016;137:938-40 e1.

- 404 11. Liao TC, Lien YT, Wang S, Huang SL, Chen CY. Comorbidity of Atopic Disorders with
405 Autism Spectrum Disorder and Attention Deficit/Hyperactivity Disorder. *J Pediatr* 2016;171:248-
406 55.
- 407 12. Leffa DT, Torres ILS, Rohde LA. A Review on the Role of Inflammation in Attention-
408 Deficit/Hyperactivity Disorder. *Neuroimmunomodulation* 2018:1-6.
- 409 13. Brunner PM, Israel A, Zhang N, et al. Early-onset pediatric atopic dermatitis is
410 characterized by TH2/TH17/TH22-centered inflammation and lipid alterations. *J Allergy Clin*
411 *Immunol* 2018;141:2094-106.
- 412 14. Esaki H, Brunner PM, Renert-Yuval Y, et al. Early-onset pediatric atopic dermatitis is
413 TH2 but also TH17 polarized in skin. *J Allergy Clin Immunol* 2016;138:1639-51.
- 414 15. Cole C, Kroboth K, Schurch NJ, et al. Filaggrin-stratified transcriptomic analysis of
415 pediatric skin identifies mechanistic pathways in patients with atopic dermatitis. *J Allergy Clin*
416 *Immunol* 2014;134:82-91.
- 417 16. van der Velden VH, Laan MP, Baert MR, de Waal Malefyt R, Neijens HJ, Savelkoul HF.
418 Selective development of a strong Th2 cytokine profile in high-risk children who develop atopy:
419 risk factors and regulatory role of IFN-gamma, IL-4 and IL-10. *Clin Exp Allergy* 2001;31:997-
420 1006.
- 421 17. Herberth G, Heinrich J, Roder S, et al. Reduced IFN-gamma- and enhanced IL-4-
422 producing CD4+ cord blood T cells are associated with a higher risk for atopic dermatitis during
423 the first 2 yr of life. *Pediatr Allergy Immunol* 2010;21:5-13.
- 424 18. Tang ML, Kemp AS, Thorburn J, Hill DJ. Reduced interferon-gamma secretion in
425 neonates and subsequent atopy. *Lancet* 1994;344:983-5.
- 426 19. Kaminishi K, Soma Y, Kawa Y, Mizoguchi M. Flow cytometric analysis of IL-4, IL-13 and
427 IFN-gamma expression in peripheral blood mononuclear cells and detection of circulating IL-13
428 in patients with atopic dermatitis provide evidence for the involvement of type 2 cytokines in the
429 disease. *J Dermatol Sci* 2002;29:19-25.

- 430 20. Kawamoto N, Kaneko H, Takemura M, et al. Age-related changes in intracellular
431 cytokine profiles and Th2 dominance in allergic children. *Pediatr Allergy Immunol* 2006;17:125-
432 33.
- 433 21. La Grutta S, Richiusa P, Pizzolanti G, et al. CD4(+)IL-13(+) cells in peripheral blood well
434 correlates with the severity of atopic dermatitis in children. *Allergy* 2005;60:391-5.
- 435 22. Campbell DE, Fryga AS, Bol S, Kemp AS. Intracellular interferon-gamma (IFN-gamma)
436 production in normal children and children with atopic dermatitis. *Clin Exp Immunol*
437 1999;115:377-82.
- 438 23. Machura E, Mazur B, Kwiecien J, Karczewska K. Intracellular production of IL-2, IL-4,
439 IFN-gamma, and TNF-alpha by peripheral blood CD3+ and CD4+ T cells in children with atopic
440 dermatitis. *Eur J Pediatr* 2007;166:789-95.
- 441 24. Antunez C, Torres MJ, Corzo JL, et al. Different lymphocyte markers and cytokine
442 expression in peripheral blood mononuclear cells in children with acute atopic dermatitis.
443 *Allergol Immunopathol (Madr)* 2004;32:252-8.
- 444 25. Leonardi S, Rotolo N, Vitaliti G, Spicuzza L, La Rosa M. IgE values and T-lymphocyte
445 subsets in children with atopic eczema/dermatitis syndrome. *Allergy Asthma Proc* 2007;28:529-
446 34.
- 447 26. Antunez C, Torres MJ, Mayorga C, et al. Cytokine production, activation marker, and
448 skin homing receptor in children with atopic dermatitis and bronchial asthma. *Pediatr Allergy*
449 *Immunol* 2006;17:166-74.
- 450 27. Chernyshov PV. Expression of activation inducer molecule (CD69) on CD3+CD8+ T
451 lymphocytes in children with atopic dermatitis correlates with SCORAD but not with the age of
452 patients. *J Eur Acad Dermatol Venereol* 2009;23:462-3.
- 453 28. Thijs J, Krastev T, Weidinger S, et al. Biomarkers for atopic dermatitis: a systematic
454 review and meta-analysis. *Curr Opin Allergy Clin Immunol* 2015;15:453-60.

- 455 29. Czarnowicki T, Esaki H, Gonzalez J, et al. Early pediatric atopic dermatitis shows only a
456 cutaneous lymphocyte antigen (CLA)(+) TH2/TH1 cell imbalance, whereas adults acquire
457 CLA(+) TH22/TC22 cell subsets. *J Allergy Clin Immunol* 2015;136:941-51 e3.
- 458 30. Czarnowicki T, Esaki H, Gonzalez J, et al. Alterations in B-cell subsets in pediatric
459 patients with early atopic dermatitis. *J Allergy Clin Immunol* 2017;140:134-44 e9.
- 460 31. Esaki H, Czarnowicki T, Gonzalez J, et al. Accelerated T-cell activation and
461 differentiation of polar subsets characterizes early atopic dermatitis development. *J Allergy Clin*
462 *Immunol* 2016;138:1473-7 e5.
- 463 32. Wu KG, Li TH, Chen CJ, Cheng HI, Wang TY. Correlations of serum Interleukin-16, total
464 IgE, eosinophil cationic protein and total eosinophil counts with disease activity in children with
465 atopic dermatitis. *Int J Immunopathol Pharmacol* 2011;24:15-23.
- 466 33. Ezzat MH, Hasan ZE, Shaheen KY. Serum measurement of interleukin-31 (IL-31) in
467 paediatric atopic dermatitis: elevated levels correlate with severity scoring. *J Eur Acad Dermatol*
468 *Venereol* 2011;25:334-9.
- 469 34. Nakazato J, Kishida M, Kuroiwa R, Fujiwara J, Shimoda M, Shinomiya N. Serum levels
470 of Th2 chemokines, CCL17, CCL22, and CCL27, were the important markers of severity in
471 infantile atopic dermatitis. *Pediatr Allergy Immunol* 2008;19:605-13.
- 472 35. Hon KL, Leung TF, Ma KC, Li AM, Wong Y, Fok TF. Serum levels of cutaneous T-cell
473 attracting chemokine (CTACK) as a laboratory marker of the severity of atopic dermatitis in
474 children. *Clin Exp Dermatol* 2004;29:293-6.
- 475 36. Leung TF, Ma KC, Hon KL, et al. Serum concentration of macrophage-derived
476 chemokine may be a useful inflammatory marker for assessing severity of atopic dermatitis in
477 infants and young children. *Pediatr Allergy Immunol* 2003;14:296-301.
- 478 37. Katsunuma T, Kawahara H, Yuki K, Akasawa A, Saito H. Impaired interferon-gamma
479 production in a subset population of severe atopic dermatitis. *Int Arch Allergy Immunol*
480 2004;134:240-7.

- 481 38. Tang ML, Kemp AS. Spontaneous expression of IL-4 mRNA in lymphocytes from
482 children with atopic dermatitis. *Clin Exp Immunol* 1994;97:491-8.
- 483 39. Teramoto T, Fukao T, Tashita H, et al. Serum IgE level is negatively correlated with the
484 ability of peripheral mononuclear cells to produce interferon gamma (IFNgamma): evidence of
485 reduced expression of IFNgamma mRNA in atopic patients. *Clin Exp Allergy* 1998;28:74-82.
- 486 40. Koning H, Neijens HJ, Baert MR, Oranje AP, Savelkoul HF. T cell subsets and cytokines
487 in allergic and non-allergic children. I. Analysis of IL-4, IFN-gamma and IL-13 mRNA expression
488 and protein production. *Cytokine* 1997;9:416-26.
- 489 41. Clark RA. Skin-resident T cells: the ups and downs of on site immunity. *J Invest*
490 *Dermatol* 2010;130:362-70.
- 491 42. Thornton CA, Upham JW, Wikstrom ME, et al. Functional maturation of
492 CD4+CD25+CTLA4+CD45RA+ T regulatory cells in human neonatal T cell responses to
493 environmental antigens/allergens. *J Immunol* 2004;173:3084-92.
- 494 43. Gasparoni A, Ciardelli L, Avanzini A, et al. Age-related changes in intracellular TH1/TH2
495 cytokine production, immunoproliferative T lymphocyte response and natural killer cell activity in
496 newborns, children and adults. *Biol Neonate* 2003;84:297-303.
- 497 44. Saule P, Trauet J, Dutriez V, Lekeux V, Dessaint JP, Labalette M. Accumulation of
498 memory T cells from childhood to old age: central and effector memory cells in CD4(+) versus
499 effector memory and terminally differentiated memory cells in CD8(+) compartment. *Mech*
500 *Ageing Dev* 2006;127:274-81.
- 501 45. Wang J, Suarez-Farinas M, Estrada Y, et al. Identification of unique proteomic
502 signatures in allergic and non-allergic skin disease. *Clin Exp Allergy* 2017;47:1456-67.
- 503 46. Brunner PM, Suarez-Farinas M, He H, et al. The atopic dermatitis blood signature is
504 characterized by increases in inflammatory and cardiovascular risk proteins. *Sci Rep*
505 2018;29:8439.

- 506 47. Brunner PM, Israel A, Zhang N, et al. Early-onset pediatric atopic dermatitis is
507 characterized by TH2/TH17/TH22-centered inflammation and lipid alterations. *J Allergy Clin*
508 *Immunol* 2018;141:2094-2106.
- 509 48. Brunner PM, Israel A, Leonard A, et al. Distinct transcriptomic profiles of early-onset
510 atopic dermatitis in blood and skin of pediatric patients. *Ann Allergy Asthma Immunol*
511 2019;122:318-330.
- 512 49. Soderlund S, Christiansson L, Persson I, et al. Plasma proteomics in CML patients
513 before and after initiation of tyrosine kinase inhibitor therapy reveals induced Th1 immunity and
514 loss of angiogenic stimuli. *Leuk Res* 2016;50:95-103.
- 515 50. Lind L, Arnlov J, Lindahl B, Siegbahn A, Sundstrom J, Ingelsson E. Use of a proximity
516 extension assay proteomics chip to discover new biomarkers for human atherosclerosis.
517 *Atherosclerosis* 2015;242:205-10.
- 518 51. Assarsson E, Lundberg M, Holmquist G, et al. Homogenous 96-plex PEA immunoassay
519 exhibiting high sensitivity, specificity, and excellent scalability. *PLoS One* 2014;9:e95192.
- 520 52. Smyth GK. Linear models and empirical Bayes methods for assessing differential
521 expression in microarray experiments. *Statistical Applications in Genetics and Molecular Biology*
522 2004;3:Article 3.
- 523 53. Esaki H, Brunner PM, Renert-Yuval Y, et al. Early onset pediatric atopic dermatitis is
524 Th2, but also Th17 polarized in skin. *J Allergy Clin Immunol* 2016;138:1639-1651.
- 525 54. Floresta G, Pistara V, Amata E, et al. Adipocyte fatty acid binding protein 4 (FABP4)
526 inhibitors. A comprehensive systematic review. *Eur J Med Chem* 2017;138:854-73.
- 527 55. Yuan D, Wu BJ, Henry A, Rye KA, Ong KL. Role of fibroblast growth factor 21 in
528 gestational diabetes mellitus: A mini-review. *Clin Endocrinol (Oxf)* 2019;90:47-55.
- 529 56. Guttman-Yassky E, Krueger JG, Lebwohl MG. Systemic immune mechanisms in atopic
530 dermatitis and psoriasis with implications for treatment. *Exp Dermatol* 2018;27:409-17.

- 531 57. Thomas MA, He J, Peterson FC, Huppler AR, Volkman BF. The Solution Structure of
532 CCL28 Reveals Structural Lability that Does Not Constrain Antifungal Activity. *J Mol Biol*
533 2018;430:3266-82.
- 534 58. Yang OO, Garcia-Zepeda EA, Walker BD, Luster AD. Monocyte chemoattractant
535 protein-2 (CC chemokine ligand 8) inhibits replication of human immunodeficiency virus type 1
536 via CC chemokine receptor 5. *J Infect Dis* 2002;185:1174-8.
- 537 59. Kelleher M, Dunn-Galvin A, Hourihane JO, et al. Skin barrier dysfunction measured by
538 transepidermal water loss at 2 days and 2 months predates and predicts atopic dermatitis at 1
539 year. *J Allergy Clin Immunol* 2015;135:930-5 e1.
- 540 60. Birch L, Perry R, Penfold C, Beynon R, Hamilton-Shield J. What change in body mass
541 index is needed to improve metabolic health status in childhood obesity: protocol for a
542 systematic review. *Syst Rev* 2016;5:120.
- 543 61. Saluja R, Khan M, Church MK, Maurer M. The role of IL-33 and mast cells in allergy and
544 inflammation. *Clin Transl Allergy* 2015;5:33.
- 545 62. Galand C, Leyva-Castillo JM, Yoon J, et al. IL-33 promotes food anaphylaxis in
546 epicutaneously sensitized mice by targeting mast cells. *J Allergy Clin Immunol* 2016;138:1356-
547 66.
- 548 63. Staumont-Salle D, Fleury S, Lazzari A, et al. CX(3)CL1 (fractalkine) and its receptor
549 CX(3)CR1 regulate atopic dermatitis by controlling effector T cell retention in inflamed skin. *J*
550 *Exp Med* 2014;211:1185-96.
- 551 64. Echigo T, Hasegawa M, Shimada Y, Takehara K, Sato S. Expression of fractalkine and
552 its receptor, CX3CR1, in atopic dermatitis: possible contribution to skin inflammation. *J Allergy*
553 *Clin Immunol* 2004;113:940-8.
- 554 65. Chong S, Lan H, Zeng K, Zhao X. Serum Fractalkine (CX3CL1) Concentration
555 Correlates with Clinical Severity in Pediatric Atopic Dermatitis Patients. *Ann Clin Lab Sci*
556 2016;46:168-73.

66. Song TW, Sohn MH, Kim ES, Kim KW, Kim KE. Increased serum thymus and activation-regulated chemokine and cutaneous T cell-attracting chemokine levels in children with atopic dermatitis. *Clin Exp Allergy* 2006;36:346-51.
67. Ahrens B, Schulz G, Bellach J, Niggemann B, Beyer K. Chemokine levels in serum of children with atopic dermatitis with regard to severity and sensitization status. *Pediatr Allergy Immunol* 2015;26:634-40.
68. Amat F, Soria A, Tallon P, et al. New insights into the phenotypes of atopic dermatitis linked with allergies and asthma in children: An overview. *Clin Exp Allergy* 2018;48:919-34.
69. Yagami A, Orihara K, Morita H, et al. IL-33 mediates inflammatory responses in human lung tissue cells. *J Immunol* 2010;185:5743-50.
70. Zoltowska AM, Lei Y, Fuchs B, Rask C, Adner M, Nilsson GP. The interleukin-33 receptor ST2 is important for the development of peripheral airway hyperresponsiveness and inflammation in a house dust mite mouse model of asthma. *Clin Exp Allergy* 2016;46:479-90.
71. Nygaard U, Hvid M, Johansen C, et al. TSLP, IL-31, IL-33 and sST2 are new biomarkers in endophenotypic profiling of adult and childhood atopic dermatitis. *J Eur Acad Dermatol Venereol* 2016;30:1930-1938.
72. Silverberg JI. Atopic dermatitis treatment: Current state of the art and emerging therapies. *Allergy Asthma Proc* 2017;38:243-9.

Figure 1




Figure 2




Figure 3

